Lunai Bioworks Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David H. Weinstein
- Full Time Employees
- 29
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2080 Century Park East Los Angeles CA United States of America 90067
- IPO Date
- Sep 30, 2025
- CIK
- 0001527728
- Website
- lunaibioworks.com
- Similar Companies
- Business
- Lunai Bioworks Inc. is a pre-clinical stage biotechnology company specializing in the research, development, and commercialization of innovative pharmaceutical, diagnostic, and biodefense products. The company operates through three primary segments: RENB, BioSymetrics, and RENC. Its core product offerings include genetically modified allogeneic dendritic cell therapeutic vaccines such as RENB-DC11, targeting solid tumors with an initial focus on pancreatic cancer, and RENB-DC20, designed for breast cancer treatment. Additionally, Lunai develops proprietary AI-powered platforms that leverage machine learning to analyze complex biomedical and genetic data for early and accurate disease diagnosis, including cancer and neurodegenerative diseases. Lunai Bioworks expanded its neurodegenerative pipeline in 2025 by launching an AI-powered Alzheimer's disease program, reflecting a strategic broadening of its therapeutic focus. The company also entered into a significant partnership with American Defense International to apply its biomedical AI platform toward accelerating the development of countermeasures for chemical and biological threats, underscoring an operational expansion into biodefense. In late 2025, Lunai secured $3.1 million in private placement funding and announced preparations for advanced clinical development stages, including formal licensing negotiations for its cancer immunotherapy platform. Founded in 2010 and headquartered in Los Angeles, California, Lunai Bioworks serves markets primarily in the United States and the Netherlands. The company leverages its expertise in AI and biotechnology to target some of the deadliest cancers, immunological diseases, and biodefense challenges. Through its comprehensive pipeline and strategic collaborations, Lunai Bioworks positions itself at the intersection of artificial intelligence, immunotherapy, and national security, aiming to deliver novel therapeutic solutions and diagnostic tools. Recent corporate changes include the acquisition of GEDi Cube International in early 2024, a name change from Renovaro Inc. back to Lunai Bioworks Inc., and ongoing capital raising initiatives to support its research and product commercialization efforts. Lunai continues to develop and integrate its proprietary machine learning pipelines to uncover clinically actionable insights and optimize its therapeutic and diagnostic product offerings across oncology, neurodegeneration, and biodefense sectors.
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers of Lunai Common Stock
Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe' ‘Naked' Short-Sellers of Lunai Common Stock
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models